Sign in
CMRAW Stock Price, Chart, Stats & News
Comera Life Sciences Holdings, Inc.
Save
Comera Life Sciences Holdings, Inc. (CMRAW) does not currently pay a dividend.
899,081
Market cap
–
Current P/E
–
Forward P/E
CMRAW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 66.77% |
Operating margin | -1890.69% |
Pretax margin | -2843.79% |
Net margin | -2843.79% |
Effective tax rate | – |
ROA | -483.06% |
ROE | 47452.88% |
D/E | -0.12x |
Interest coverage ratio | -587.02x |
CMRAW valuation
P/E | – |
P/S | 0.00x |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.02x |
About
Comera Life Sciences Holdings, Inc. is an early-stage life sciences company dedicated to developing its own innovative therapeutics. These treatments leverage its unique SQore formulation platform, which is engineered to convert biologics typically administered intravenously (IV) into convenient subcutaneous (SQ) versions. The company's pipeline currently features two primary drug candidates: CLS-001, an improved biologic in preclinical development, targets Crohn's and Ulcerative Colitis; and CLS-002, also in preclinical stages, is an enhanced biologic aimed at various oncological indications.
Similar securities
Based on sector and market capitalization
Report issue